Shares of Sanofi (NYSE:SNY) have been given a consensus recommendation of “Hold” by the fourteen brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $53.50.
A number of equities analysts have commented on the company. Cowen and Company reissued a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Argus reissued a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th.
TRADEMARK VIOLATION NOTICE: “Sanofi (SNY) Receives Average Rating of “Hold” from Brokerages” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.com-unik.info/2017/11/03/sanofi-sny-receives-average-rating-of-hold-from-brokerages.html.
In other news, major shareholder Sanofi purchased 60,595 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were acquired at an average price of $478.98 per share, with a total value of $29,023,793.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC increased its holdings in Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC increased its holdings in Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares during the last quarter. Toronto Dominion Bank increased its holdings in Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after purchasing an additional 180 shares during the last quarter. Finally, River Road Asset Management LLC bought a new stake in Sanofi in the third quarter valued at about $208,000. Institutional investors and hedge funds own 9.35% of the company’s stock.
Shares of Sanofi (SNY) traded down $0.76 during trading on Friday, hitting $45.72. 388,078 shares of the stock were exchanged, compared to its average volume of 1,530,785. The firm has a market capitalization of $116,544.10, a price-to-earnings ratio of 14.58 and a beta of 0.88.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. The company had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 18.89% and a net margin of 25.44%. The company’s quarterly revenue was down 2.3% on a year-over-year basis. equities analysts predict that Sanofi will post 3.3 EPS for the current year.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.